Axert en es it fr

Axert Brand names, Axert Analogs

Axert Brand Names Mixture

  • No information avaliable

Axert Chemical_Formula


Axert RX_link

Axert fda sheet

Axert FDA

Axert msds (material safety sheet)

Axert Synthesis Reference

No information avaliable

Axert Molecular Weight

335.465 g/mol

Axert Melting Point

No information avaliable

Axert H2O Solubility

No information avaliable

Axert State


Axert LogP


Axert Dosage Forms


Axert Indication

For the treatment of acute migraine headache in adults

Axert Pharmacology

Almotriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Almotriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Almotriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT1D family) having only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Almotriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Almotriptan in humans.

Axert Absorption

No information avaliable

Axert side effects and Toxicity

No information avaliable

Axert Patient Information

No information avaliable

Axert Organisms Affected

Humans and other mammals